Additionally, the combination of measuring decorin levels and performing standard diagnostic tools such as pulse wave velocity measurements may be beneficial to the early detection of subclinical vasculopathy, which can then allow physicians to implement personalized and patient-centered treatment strategies in a timely manner. This evidence concerns the gene DCN and vascular disorder.